Endocrine Pharmacology: Thyroid Hormones and Antithyroid Drugs

Introduction / Overview

Thyroid hormones represent a cornerstone of endocrine pharmacology, governing metabolic activity, growth, and development across a spectrum of physiological processes. Disruptions in thyroid hormone production or action give rise to clinically significant disorders, most notably hyperthyroidism and hypothyroidism. Pharmacologic modulation of thyroid hormone synthesis, secretion, and action therefore occupies a pivotal role in both acute and chronic disease management. Clinicians and pharmacists must maintain a thorough understanding of the agents that influence thyroid activity, ranging from synthetic thyroxine preparations to iodine-containing compounds and organosilicon antithyroid drugs.

• Learning Objectives
• Identify the primary thyroid hormones and their biosynthetic pathways.
• Describe the pharmacodynamic mechanisms of antithyroid drugs and iodine-based therapies.
• Explain the pharmacokinetic properties that influence dosing strategies for thyroid hormone replacements and antithyroid agents.
• Recognize common and serious adverse effects associated with thyroid hormone and antithyroid drug therapy.
• Appreciate special considerations in pregnancy, lactation, pediatrics, and patients with organ dysfunction.

Classification

Thyroid Hormone Preparations

• Levothyroxine (T₄) – synthetic dioxothyronine, commonly used for hypothyroidism.
• Liothyronine (T₃) – synthetic triiodothyronine, employed in specific clinical scenarios where rapid correction of thyroid hormone deficiency is required.
• Combination preparations (e.g., levothyroxine/liothyronine) – designed to mimic endogenous hormone ratios.
• Natural thyroid extracts – derived from porcine thyroid glands; contain a mixture of T₄, T₃, and minor thyroxine analogues.

Antithyroid Drugs

• Organosilicon Compounds – propylthiouracil (PTU) and methimazole (MMI), both inhibiting thyroid peroxidase (TPO).
• Monoiodinated Compounds – potassium iodide (KI), sodium perchlorate, and potassium perchlorate, acting primarily via the Wolff–Chaikoff effect.
• Combination Preparations – e.g., propylthiouracil plus potassium iodide for refractory hyperthyroidism.

Other Agents Affecting Thyroid Physiology

• Beta‑blockers (e.g., propranolol) – mitigate adrenergic symptoms without altering hormone synthesis.
• Glucocorticoids – reduce peripheral conversion of T₄ to T₃ and suppress autoimmune activity.
• Somatostatin analogues – inhibit thyroid hormone release in select cases.

Mechanism of Action

Thyroid Hormone Biosynthesis and Secretion

Thyroid hormone synthesis initiates with iodide uptake via the sodium–iodide symporter (NIS) expressed on the basolateral membrane of thyrocytes. Iodide is oxidized by thyroid peroxidase (TPO) to form iodine, which subsequently iodinated tyrosyl residues on thyroglobulin (Tg). Coupling reactions yield T₄ and T₃, which are stored within the colloid of the thyroid follicle. Upon stimulation by thyroid stimulating hormone (TSH), proteolytic cleavage of Tg releases active hormones into the bloodstream.

Pharmacodynamics of Antithyroid Drugs

Organosilicon Inhibitors (PTU, MMI)

PTU and MMI competitively inhibit TPO, thereby decreasing iodination of tyrosyl residues and subsequent coupling reactions. PTU possesses an additional activity: it impedes the peripheral conversion of T₄ to T₃ by inhibiting type I 5′‑deiodinase. This dual action renders PTU particularly effective in thyrotoxic crisis where rapid suppression of peripheral T₃ levels is desired. MMI, in contrast, lacks significant deiodinase inhibition and is preferred for long‑term management due to a lower risk of hepatotoxicity.

Monoiodinated Compounds (KI, Perchlorate)

High intracellular iodide concentrations trigger the Wolff–Chaikoff effect, transiently inhibiting TPO activity and reducing hormone synthesis. Persistent inhibition requires the release of iodide from the follicular lumen (the “escape” phenomenon). Perchlorate antagonizes NIS, blocking iodide uptake and enhancing urinary excretion. Combination therapy with potassium iodide and perchlorate is occasionally employed for refractory cases, yet the benefit must be weighed against additive toxicity.

Other Therapeutic Mechanisms

Beta‑blockers competitively inhibit β‑adrenergic receptors, attenuating sympathetic manifestations of thyrotoxicosis (tachycardia, tremor) without affecting hormone synthesis. Glucocorticoids suppress the hypothalamic–pituitary–thyroid axis, reduce peripheral conversion, and mitigate autoimmune aggression in Graves’ disease. Somatostatin analogues block TSH‑mediated stimulation via paracrine inhibition of thyrotropin‑releasing hormone (TRH) release.

Pharmacokinetics

Thyroid Hormone Preparations

Levothyroxine (T₄)

Levothyroxine is absorbed mainly in the small intestine, with peak plasma concentrations achieved within 4–6 h. Oral bioavailability approximates 70–80 % in euthyroid patients, but absorption may be significantly reduced by concomitant calcium or iron supplements, antacids, or high‑fiber diets. Distribution is extensive; ~80 % of the drug binds to plasma proteins, primarily thyroxine-binding globulin (TBG), transthyretin, and albumin. The volume of distribution (V_d) is approximately 0.6 L kg⁻¹. Metabolism occurs via deiodination, glucuronidation, and sulfation, while excretion is predominantly renal (≈70 %) and fecal (≈20 %). The terminal half‑life (t_1/2) ranges from 7–10 days in adults, extending to 10–14 days in elderly patients. Dosing adjustments are required for patients with hepatic impairment (reduced clearance) and for those on cholestyramine or bile acid sequestrants (increased clearance). The recommended starting dose in adults is 1.6 µg kg⁻¹ day⁻¹, with titration guided by free T₄ and TSH levels.

Liothyronine (T₃)

Liothyronine displays rapid absorption, with peak concentrations at 1–3 h post‑dose. Oral bioavailability is approximately 50–70 %. Plasma protein binding is lower (~20 %) compared to levothyroxine, allowing a larger free fraction. The volume of distribution is 0.2 L kg⁻¹. Metabolism proceeds through deiodination and conjugation, with renal excretion constituting the main elimination route. The half‑life is shorter, ranging from 6–8 h, necessitating twice‑daily dosing to maintain stable serum levels. Because of its rapid onset, liothyronine is reserved for specific indications such as refractory hypothyroidism or to assess euthyroid status during levothyroxine therapy.

Combination Preparations

Products containing both T₄ and T₃ aim to approximate endogenous hormone ratios. Pharmacokinetics mirror the individual components, with the T₄ component contributing to long‑term euthyroidism and the T₃ component providing acute metabolic effects. Dose titration must incorporate both free T₄ and TSH measurements.

Antithyroid Drugs

Propylthiouracil (PTU)

PTU is absorbed efficiently from the gastrointestinal tract, reaching peak plasma concentrations within 1–2 h. The drug demonstrates a V_d of 0.5 L kg⁻¹ and is highly protein‑bound (~70 %). Metabolism occurs via glucuronidation and sulfation, followed by renal clearance. The terminal half‑life is approximately 1–2 h, but its inhibitory effect on TPO persists due to the irreversible binding to the enzyme. PTU is contraindicated in pregnancy after the first trimester due to teratogenic potential, and its hepatotoxicity profile necessitates periodic liver function monitoring.

Methimazole (MMI)

MMI is absorbed rapidly, with peak concentrations at 1–3 h. It has a V_d of 0.3 L kg⁻¹ and is bound to plasma proteins at 40–50 %. Metabolism involves glucuronidation and sulfation; hepatic clearance predominates. The half‑life is around 12–24 h, allowing once‑daily dosing. MMI is generally preferred for long‑term therapy because of its lower risk of hepatic injury compared to PTU.

Potassium Iodide (KI)

KI is absorbed quickly from the gastrointestinal tract, with peak plasma levels achieved within 30 min. Distribution is rapid, with iodide entering the thyroid gland via NIS. The drug is metabolized to iodide and excreted unchanged in the urine, with a half‑life of approximately 1–2 h. KI’s effect on hormone synthesis is transient; prolonged administration may lead to escape from the Wolff–Chaikoff effect.

Perchlorate

Perchlorate is absorbed orally and distributed systemically. It binds competitively to NIS, blocking iodide uptake. The drug is primarily excreted unchanged in the urine, with a half‑life of 4–6 h. Perchlorate’s pharmacologic effect is limited by the need for continuous dosing and potential for iodide deficiency.

Therapeutic Uses / Clinical Applications

Thyroid Hormone Replacement

• Levothyroxine – primary treatment for hypothyroidism secondary to autoimmune thyroiditis, post‑thyroidectomy, or radiation therapy.
• Liothyronine – indicated when rapid correction of severe hypothyroidism is required, or when levothyroxine alone fails to normalize free T₃ levels.
• Combination preparations – employed in select cases of refractory hypothyroidism or when patient preference dictates a mixture of synthetic hormones.
• Natural thyroid extracts – used in patients who experience adverse reactions to synthetic preparations or who prefer an animal‑derived product.

Antithyroid Therapy

• PTU and MMI – first‑line agents for hyperthyroidism, including Graves’ disease and toxic multinodular goiter. PTU is preferred in thyrotoxic crisis due to deiodinase inhibition, whereas MMI is favored for long‑term management.
• Potassium iodide – administered pre‑operatively to reduce vascularity of the thyroid gland and to treat acute thyroid storm.
• Perchlorate – used adjunctively in refractory hyperthyroidism, particularly when TPO inhibitors are ineffective.

Adjunctive Pharmacologic Interventions

• Beta‑blockers – provide symptomatic relief of adrenergic manifestations in thyrotoxicosis.
• Glucocorticoids – utilized in thyroid storm to suppress peripheral conversion and reduce inflammation.
• Somatostatin analogues – employed off‑label in cases of refractory Graves’ disease to inhibit TSH release.

Adverse Effects

Thyroid Hormone Preparations

• Excessive dosing may precipitate atrial fibrillation, heart failure, and osteoporosis.
• Insufficient dosing can lead to persistent fatigue, weight gain, and cold intolerance.
• Drug interactions with calcium, iron, and antacids may reduce absorption.
• Hypersensitivity reactions to natural thyroid extracts are rare but possible.

Antithyroid Drugs

PTU

• Hepatotoxicity – acute liver failure reported in a minority of patients; periodic liver function monitoring is advisable.
• Allergic reactions – rash, eosinophilia, and agranulocytosis.
• atogenicity – fetal malformations reported when used during the first trimester; contraindicated in pregnancy.

MMI

• Peripheral neuropathy – characterized by numbness and tingling; usually reversible upon discontinuation.
• Hepatotoxicity – less frequent than PTU but still a concern; liver function tests recommended.
• Allergic reactions – rash and eosinophilia.

KI

• Thyroid storm – paradoxical increase in hormone synthesis if administered after the escape phenomenon has occurred.
• Allergic reactions – anaphylaxis in rare cases.
• Iodine deficiency – prolonged use may precipitate hypothyroidism.

Perchlorate

• Thyroid dysfunction – may cause hypothyroidism if used excessively.
• Allergic reactions – rarely reported.

Drug Interactions

Thyroid Hormone Preparations

• Calcium, iron, antacids, and cholestyramine – reduce absorption, necessitating dose adjustments.
• Oral contraceptives – alter TBG levels, potentially modifying free hormone concentrations.
• Warfarin – thyroid hormone levels may influence anticoagulant requirements.

Antithyroid Drugs

• PTU and MMI – may potentiate the effects of anticoagulants and increase bleeding risk.
• Glucocorticoids – suppress TSH, potentially reducing antithyroid drug efficacy.
• Beta‑blockers – may mask hyperthyroid symptoms, delaying diagnosis of drug failure.

Special Considerations

Pregnancy and Lactation

• Levothyroxine is the preferred treatment for hypothyroidism during pregnancy, as adequate maternal thyroid hormone is essential for fetal neurodevelopment.
• PTU is recommended during the first trimester due to lower teratogenic risk; MMI is considered after week 12.
• Beta‑blockers may cross the placenta; careful selection and dosing are required.
• Thyroid hormone therapy is considered safe for lactation; breast milk levels are negligible.

Pediatric Considerations

• Dosing is weight‑based; typical levothyroxine dose is 10–15 µg kg⁻¹ day⁻¹.
• Growth monitoring is essential; excessive dosing may impair linear growth.
• Antithyroid drug monitoring must account for higher hepatic metabolism rates in children.

Geriatric Considerations

• Reduced hepatic and renal clearance may prolong drug half‑life; dose reductions are often necessary.
• Polypharmacy increases the risk of drug interactions; careful review of concomitant medications is advised.
• Cardiovascular comorbidities heighten the risk of arrhythmias with thyroid hormone excess.

Renal and Hepatic Impairment

• Thyroid hormone clearance is reduced in hepatic dysfunction; dose adjustments should be guided by free T₄ and TSH values.
• Renal impairment has modest effects on levothyroxine pharmacokinetics; monitoring remains essential to avoid accumulation.
• PTU and MMI hepatic metabolism necessitates caution in patients with liver disease; periodic liver function testing is recommended.

Summary / Key Points

• Thyroid hormones are central to metabolic regulation; their pharmacologic manipulation requires precise dosing and monitoring.
• Organosilicon antithyroid drugs inhibit TPO, with PTU additionally blocking peripheral deiodination.
• High‑iodide therapy exploits the Wolff–Chaikoff effect but must be timed correctly to avoid thyroid storm.
• Drug interactions affecting absorption, metabolism, and clearance influence therapeutic outcomes; vigilant review of concomitant medications is imperative.
• Special populations—including pregnant, lactating, pediatric, geriatric, and patients with organ dysfunction—demonstrate distinct pharmacokinetic and pharmacodynamic profiles necessitating individualized care.

Mastery of thyroid hormone pharmacology equips clinicians and pharmacists with the tools necessary to manage thyroid disorders effectively and safely, ensuring optimal patient outcomes across diverse clinical settings.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.